Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q1 2016 · 10-Q
Revenue$29.01M$29.01M+67.0% vs Q1 2015 Net Income$11.22M$11.22M−71.7% vs Q1 2015 EPS Diluted-$0.08-$0.08N/M vs Q1 2015 Operating Income-$8,241,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
Free Cash Flowderived-$3,591,000N/M Margins · derivedOperating margin-28.4%+18.2 pt vs Q1 2015
Net margin38.7%
ended Mar 31, 2016 · filed May 5, 2016 · 35 d after period end